Skip to main content

AEterna Zentaris Inc. (AEZS)

NASDAQ: AEZS · IEX Real-Time Price · USD
0.613 0.002 (0.38%)
Sep 23, 2021 1:33 PM EDT - Market open
Market Cap75.48M
Revenue (ttm)3.65M
Net Income (ttm)-5.12M
Shares Out121.30M
EPS (ttm)-0.07
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume282,208
Open0.610
Previous Close0.611
Day's Range0.605 - 0.622
52-Week Range0.290 - 3.620
Beta2.22
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 4, 2021

About AEZS

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maxi...

IndustryBiotechnology
IPO DateJul 18, 1996
CEOKlaus Paulini
Employees12
Stock ExchangeNASDAQ
Ticker SymbolAEZS
Full Company Profile

Financial Performance

In 2020, AEZS's revenue was $3.65 million, an increase of 586.47% compared to the previous year's $532,000. Losses were -$5.12 million, -15.29% less than in 2019.

Financial Statements

News

Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified ...

2 weeks ago - GlobeNewsWire

Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing

CHARLESTON, S.C., July 29, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a ...

1 month ago - GlobeNewsWire

Best Penny Stocks To Buy Now? 7 To Watch This Week

What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?

Other symbols:AMRNDRRXGLBSLOTZMDWD
3 months ago - PennyStocks

Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs

– Dr. Levy is a well-established n euroimmunologist with extensive experience and expertise in the area of neuroimmunology, autoimmune and CNS disorders

3 months ago - GlobeNewsWire

Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit

CHARLESTON, S.C., June 03, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a ...

3 months ago - GlobeNewsWire

Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a P...

- Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property and know-how developed by the University related to the therapeutic use of m acimorelin for the ...

4 months ago - GlobeNewsWire

Aeterna Zentaris Starts Research Study On How Well Macimorelin Works For Growth Hormone Deficiency Diagnosis

Aeterna Zentaris Inc (NASDAQ: AEZS) has commenced its pivotal Phase 3 DETECT trial evaluating macimorelin as a diagnosis of childhood-onset growth hormone deficiency (CGHD). The investigational new drug...

4 months ago - Benzinga

Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

– Safety and efficacy study for macimorelin initiated as agreed with U . S . FDA and the European Medicines Agency ("EMA") in the Company's Pediatric Investigation Plan ("PIP")

4 months ago - GlobeNewsWire

Aeterna Zentaris to Present at the Q2 Virtual Investor Summit

– Live video webcast with CEO, Dr. Klaus Paulini, on Monday, May 17, 2021 at 8:45 AM ET

4 months ago - GlobeNewsWire

Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders

CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a d...

4 months ago - GlobeNewsWire

Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates

– Q1 2021 marked by solid operational execution with expansion and diversification of pipeline , intellectual property and portfolio of assets

4 months ago - GlobeNewsWire

Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientif...

– Over 20 years of industry experience in translating research into clinical development in a wide range of therapeutic areas of endocrinology and oncology

4 months ago - GlobeNewsWire

Aeterna Zentaris Announces Virtual 2021 Annual Meeting of Shareholders

CHARLESTON, S.C., April 28, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing t...

4 months ago - GlobeNewsWire

3 Penny Stocks to Watch During the Last Week of April

As April comes to an end, are these 3 penny stocks worth watching? The post 3 Penny Stocks to Watch During the Last Week of April appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...

Other symbols:MICTZSAN
4 months ago - PennyStocks

Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results

– Company executing on growth strategy to build-out pipeline of development assets

5 months ago - GlobeNewsWire

Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement

CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing t...

6 months ago - GlobeNewsWire

AEZS Stock: Why Aeterna Zentaris Shares Are Shooting Higher Today

Investors in AEZS stock have continued to pile into this trade today, with the stock up more than 40% on news around its Covid-19 vaccine. The post AEZS Stock: Why Aeterna Zentaris Shares Are Shooting H...

6 months ago - InvestorPlace

Aeterna Zentaris Shares Are Trading Higher On Announcing Licensing Pact For Development Of Prophylactic COVID-19 Vacc...

Aeterna Zentaris Inc (NASDAQ: AEZS) has exercised its option announced on February 2, and entered into an exclusive worldwide sub-licensable patent and know-how license agreement for a potential COVID-1...

6 months ago - Benzinga

Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerz...

- Company secures next step to continue to build-out pipeline of assets

6 months ago - GlobeNewsWire

If You Like Long Shots, Aeterna Zentaris Stock Is Worth a Gamble

AEZS stock isn't something to bet your entire portfolio on, but since the company's a Covid-19 vaccine contender, it might be worth owning. The post If You Like Long Shots, Aeterna Zentaris Stock Is Wor...

6 months ago - InvestorPlace

Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program fo...

– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which will ...

6 months ago - GlobeNewsWire

Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference

CHARLESTON, S.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics an...

6 months ago - GlobeNewsWire

Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares

CHARLESTON, S.C., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing th...

7 months ago - GlobeNewsWire

Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to $29.7 Million

CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing th...

7 months ago - GlobeNewsWire